--- title: "Omeros Corporation (OMER.US)" type: "Symbol" locale: "en" url: "https://longbridge.com/en/quote/OMER.US.md" symbol: "OMER.US" name: "Omeros Corporation" industry: "Pharmaceuticals" datetime: "2026-05-19T22:33:26.409Z" locales: - [en](https://longbridge.com/en/quote/OMER.US.md) - [zh-CN](https://longbridge.com/zh-CN/quote/OMER.US.md) - [zh-HK](https://longbridge.com/zh-HK/quote/OMER.US.md) --- # Omeros Corporation (OMER.US) ## Company Overview Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. | Item | Detail | |------|--------| | Industry | Pharmaceuticals | | Exchange | US Market | | Website | [www.omeros.com](https://www.omeros.com) | ## Key Drivers > *AI-analyzed key factors driving this stock's performance* ## Longbridge Financial Score™: D > *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge* > Updated: 2026-05-19T04:30:13.000Z **Overall: D (0.72)** **Industry**: Pharmaceuticals | Metric | Value | |--------|-------| | Industry Ranking | 135 / 190 | | Industry Median | C | | Industry Average | C | - **Style**: Value - Stocks where the company's main business is in a mature stage. - **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns. **Multi Score**: D #### Style Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Revenue YoY | 0.00% | | | Net Profit YoY | 156.29% | | | P/B Ratio | -13.37 | | | Dividend Ratio | 0.00% | | #### Size Score Score: | Indicator | Value | Rating | |-----------|-------|--------| | Market Cap | 846791653.50 | | | Revenue | 9893000.00 | | #### Multi Score Score: D | Indicator | Value | Rating | |-----------|-------|--------| | ROE | -60.68% | E | | Profit Margin | 871.02% | A | | Gross Margin | 54.34% | B | | Revenue YoY | 0.00% | C | | Net Profit YoY | 156.29% | A | | Total Assets YoY | 21.69% | A | | Net Assets YoY | 70.34% | A | | Cash Flow Margin | -109.97% | E | | OCF YoY | 0.00% | D | | Turnover | 0.04 | E | | Gearing Ratio | 122.13% | E | ```chart-data:radar { "title": "Longbridge Financial Score - Omeros Corporation", "chart_type": "radar", "dimensions": [ { "name": "Style Score", "grade": "", "indicators": [ { "name": "Revenue YoY", "value": "0.00%", "rating": "" }, { "name": "Net Profit YoY", "value": "156.29%", "rating": "" }, { "name": "P/B Ratio", "value": "-13.37", "rating": "" }, { "name": "Dividend Ratio", "value": "0.00%", "rating": "" } ] }, { "name": "Size Score", "grade": "", "indicators": [ { "name": "Market Cap", "value": "846791653.50", "rating": "" }, { "name": "Revenue", "value": "9893000.00", "rating": "" } ] }, { "name": "Multi Score", "grade": "D", "indicators": [ { "name": "ROE", "value": "-60.68%", "rating": "E" }, { "name": "Profit Margin", "value": "871.02%", "rating": "A" }, { "name": "Gross Margin", "value": "54.34%", "rating": "B" }, { "name": "Revenue YoY", "value": "0.00%", "rating": "C" }, { "name": "Net Profit YoY", "value": "156.29%", "rating": "A" }, { "name": "Total Assets YoY", "value": "21.69%", "rating": "A" }, { "name": "Net Assets YoY", "value": "70.34%", "rating": "A" }, { "name": "Cash Flow Margin", "value": "-109.97%", "rating": "E" }, { "name": "OCF YoY", "value": "0.00%", "rating": "D" }, { "name": "Turnover", "value": "0.04", "rating": "E" }, { "name": "Gearing Ratio", "value": "122.13%", "rating": "E" } ] } ] } ``` ## Valuation Analysis | Metric | Current | Industry Ranking | High | Median | Low | |--------|---------|-----------------|------|--------|-----| | PE (TTM) | 9.83 | 11/190 | - | - | - | | PB | -13.37 | 224/190 | - | - | - | | PS (TTM) | 85.60 | 149/190 | - | - | - | | Dividend Yield | 0.00% | - | - | - | - | ## Peer Comparison | Rank | Name | Profit | Growth | Operation | Security | Cash | Rating | | --- | --- | --- | --- | --- | --- | --- | --- | | 01 | Cormedix (CRMD.US) | A | A | B | C | B | A | | 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B | | 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B | | 04 | Roche (RHHBY.US) | A | B | B | D | B | B | | 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B | ## Institutional View ### Analyst Rating Distribution > As of 2026-05-15T04:00:00.000Z Total Analysts: **4** | Rating | Count | Percentage | |--------|-------|-----------| | Buy | 2 | 50% | | Hold | 2 | 50% | ### Target Price Forecast | Metric | Price | |--------|-------| | Current Price | 11.97 | | Highest Target | 40.00 | | Lowest Target | 36.00 | ## References - [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OMER.US/overview.md) - [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OMER.US/norm.md) - [Related News](https://longbridge.com/en/quote/OMER.US/news.md) - [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OMER.US/filings.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**